Bioventus (BVS) Earnings Analysis
Bioventus (BVS) has no confirmed upcoming earnings date. Last quarter (2026-03-05) it beat with EPS 0.24 USD vs 0.22 USD est (+9.1%). It has beaten estimates in 2/2 recent quarters (100%). Trailing P/E 27.47.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does BVS next report earnings?
No confirmed upcoming earnings date is currently scheduled for BVS. This page updates as the calendar is published.
BVS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-03-05 | 0.24 USD | 0.22 USD | +9.1% | Beat |
| 2025-03-11 | 0.15 USD | 0.08 USD | +87.5% | Beat |
Beat rate: 2/2 (100%) over reported quarters with consensus data.
BVS valuation and analyst view
| Trailing P/E | 27.47 |
|---|---|
| Trailing EPS | 0.42323 USD |
| Price / book | 4.14 |
| Dividend yield | 0.00% |
| Market cap | 0.79B |
| Analyst consensus | Buy (4 buy / 2 hold / 0 sell) |
| Avg price target | 15 USD |
Related research pages
Frequently asked questions
When is Bioventus (BVS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for BVS. This page updates as the calendar is published.
Did BVS beat earnings last quarter?
In its 2026-03-05 report, BVS posted EPS of 0.24 USD versus a 0.22 USD estimate — a beat of 9.1%.
What is BVS's earnings track record?
Over the last 2 reported quarters with consensus data, BVS beat estimates 2 times (100%).
What is BVS's current P/E ratio and EPS?
BVS trades at a trailing P/E of 27.47 on trailing EPS of 0.423232551620641 USD.
What do analysts rate BVS?
Analyst consensus is "Buy" across 6 ratings (0 strong buy, 4 buy, 2 hold, 0 sell, 0 strong sell). Average 12-month price target: 15 USD.